Rituximab News and Research

RSS
Rituximab is approved by the Food and Drug Administration (FDA) to be used alone or with other drugs to treat certain types of B-cell non-Hodgkin lymphoma. It is also approved to be used with methotrexate to treat rheumatoid arthritis. Rituximab is also being studied in the treatment of other types of cancer and other conditions.
Rituximab may be effective in treating membranous nephropathy

Rituximab may be effective in treating membranous nephropathy

Study of Rituxan (rituximab) in lupus nephritis misses primary endpoint

Study of Rituxan (rituximab) in lupus nephritis misses primary endpoint

Rituximab useful for advanced indolent lymphoma

Rituximab useful for advanced indolent lymphoma

Rituximab reduces kidney inflammation in patients with severe lupus nephritis

Rituximab reduces kidney inflammation in patients with severe lupus nephritis

Rituximab maintenance therapy improves survival in patients with relapsed follicular lymphoma

Rituximab maintenance therapy improves survival in patients with relapsed follicular lymphoma

Xencor presents data on anti-CD19 and anti-CD40 antibodies

Xencor presents data on anti-CD19 and anti-CD40 antibodies

Intense chemo wards off recurrence in half of mantle cell lymphoma patients after seven years

Intense chemo wards off recurrence in half of mantle cell lymphoma patients after seven years

Statins do not interfere with Rituximab treatment for lymphomas

Statins do not interfere with Rituximab treatment for lymphomas

Rituxan in combination with chemo improves survival in chronic lymphocytic leukemia

Rituxan in combination with chemo improves survival in chronic lymphocytic leukemia

Novel therapeutic approaches for various forms of thrombocytopenia

Novel therapeutic approaches for various forms of thrombocytopenia

FDA accepts Zevalin supplemental biologics license application

FDA accepts Zevalin supplemental biologics license application

Novel concept in chronic lymphoid leukemia treatment

Novel concept in chronic lymphoid leukemia treatment

Novel leukemia therapy shows promise for high-risk patients

Novel leukemia therapy shows promise for high-risk patients

Infant deaths in clinical drug trials in India raise concern about ethical standards

Infant deaths in clinical drug trials in India raise concern about ethical standards

NCI awards Wilmot scientists $1.6 million to study lymphoma treatments

NCI awards Wilmot scientists $1.6 million to study lymphoma treatments

Rituximab significantly reduces kidney injury in membranous nephropathy

Rituximab significantly reduces kidney injury in membranous nephropathy

Access to rheumatoid arthritis drugs 'curbed' for sufferers in the UK

Access to rheumatoid arthritis drugs 'curbed' for sufferers in the UK

Modified chemotherapy regimen promising for lymphoma patients in the developing world

Modified chemotherapy regimen promising for lymphoma patients in the developing world

Tuberculosis not the only risk from new immunological drugs

Tuberculosis not the only risk from new immunological drugs

Drugs in the pipeline: new therapies that could change treatment strategies

Drugs in the pipeline: new therapies that could change treatment strategies